Recent Updates — ENLV
The Nasdaq Stock Market notified Enlivex that its ordinary shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days ending October 22, 2026. Because Enlivex executed a reverse split within the prior year, it is ineligible for the standard 180-day cure period. The company has implemented a 1-for-16 reverse stock split effective immediately and intends to appeal the delisting determination via an oral hearing before the Nasdaq Hearings Panel. Trading will continue during the appeal process, though success is not guaranteed. Enlivex operates in the biotechnology sector, developing immunotherapies for aging-related conditions while maintaining a digital asset treasury.
Shareholders approved a 1-for-16 reverse stock split, reducing authorized shares from 158.3 million to 9.9 million and outstanding shares from approximately 24.5 million to roughly 1.5 million. The split becomes effective on October 27, 2026, with trading beginning on a split-adjusted basis under the symbol ENLV. Fractional shares will be rounded up to the nearest whole share, and warrant and option exercise prices will adjust proportionately. Enlivex is a longevity company developing Allocetra immunotherapy for age-related osteoarthritis while operating a prediction markets treasury.
Enlivex announced an immediate cost reduction plan designed to lower cash burn and concentrate resources on its Phase 2b clinical trial of Allocetra for knee osteoarthritis. The company is winding down all non-clinical R&D activities, reducing its workforce by approximately 60%, cutting management salaries by 20%, and lowering the CEO's compensation by 40%. Topline six-month data from the trial is expected by mid-2027. Enlivex operates in the biotechnology sector, developing immunotherapies for aging-related conditions while maintaining a digital asset treasury strategy.
Enlivex Ltd. filed an amendment to its Form 6-K to update proxy materials for an Extraordinary General Meeting of Shareholders scheduled for October 16, 2026. The primary proposal seeks shareholder approval for a reverse share split of ordinary shares at a ratio between 1-for-13 and 1-for-16, with the Board authorized to select the final ratio within this range. Additionally, shareholders are asked to authorize the Board to effect one or more additional reverse splits within 12 months, with an aggregate ratio ranging from 1-for-2 to 1-for-1,000. The company states these actions aim to increase the share price to meet Nasdaq's minimum bid price requirement of $1.00 per share and avoid potential delisting. Enlivex Ltd. operates in the biotechnology industry, focusing on developing cancer immunotherapies.
Enlivex Ltd. announced that the record date for its Extraordinary General Meeting of Shareholders, scheduled for October 14, 2026, has been revised to October 1, 2026, from the previously disclosed October 5, 2026. The meeting will seek shareholder approval for a reverse stock split of the company's ordinary shares at a ratio of 1-for-16. This action is intended to increase the market price of the shares to satisfy Nasdaq’s continued listing requirement of maintaining a minimum bid price of $1.00 per share, as the shares have closed below this threshold for consecutive trading days. The split will be effective as soon as possible following shareholder approval and requires amending the Articles of Association. Enlivex Ltd. operates in the biotechnology industry, focusing on the development of cancer immunotherapies.
Enlivex Ltd. announced an Extraordinary General Meeting of Shareholders scheduled for October 14, 2026, to vote on a proposed reverse stock split of its ordinary shares at a ratio of 1-for-16. The company states the primary purpose is to increase the market price of its shares to satisfy Nasdaq’s continued listing requirement of maintaining a minimum bid price of $1.00 per share, as the shares have closed below this threshold for each trading day from September 10, 2026, through the filing date. If approved, the split will be effective as soon as possible following shareholder approval, and the company’s Articles of Association will be amended accordingly. The record date for voting is October 5, 2026. Enlivex Ltd. operates in the biotechnology industry, focusing on the development of cancer immunotherapies.